Skip to main content
. 2018 Aug 6;115(34):E8057–E8066. doi: 10.1073/pnas.1721815115

Fig. 2.

Fig. 2.

Peripheral AT2R/TRPA1 inhibition attenuates neuropathic pain hypersensitivity. (A) TRPA1 antagonist A967079, but not TRPV1 antagonist AMG9810 (30 mg/kg for each, i.p.), attenuates SNI-induced mechanical hypersensitivity. Rectangular boxes denote postdrug administration behavioral assessment time points. Mean ± SEM; *P < 0.05, **P < 0.01, and ***P < 0.001 vs. sham-A967079/AMG9810 groups; not significant (ns) vs. sham-A967079 group, n = 8 mice per group. (B) TRPA1 antagonist A967079 attenuates SNI-induced cold hypersensitivity. Rectangular box denotes postdrug administration behavioral assessment time point. Mean ± SEM; ***P < 0.001 vs. sham-A967079 group; ##P < 0.01 and ###P < 0.001 vs. SNI-saline group. (C) Coadministration of the AT2R antagonist PD123319 (3 mg/kg, i.p.) and the TRPA1 antagonist A967079 (10 mg/kg, i.p.) does not additively reverse SNI-induced mechanical (Left) or cold hypersensitivity (Right). Rectangular boxes denote postdrug administration behavioral assessment time points. Mean ± SEM; *P < 0.05, **P < 0.01, and ***P < 0.001 vs. respective SNI-contralateral groups; #P < 0.05 vs. 10d-BL time point.